The U.S. Food and Drug Administration (FDA) approved a new medication to treat clinical depression in Adults. A total of six clinical studies were conducted to garner FDA’s drug approval. The new drug is called Brintellix by Takeda Pharmaceutical & H. Lundbeck. Brintellix will be available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. Nausea appears to be a side effect reported by some patients.

The manufacturer reports that the new drug is an inhibitor of serotonin (5-HT) reuptake, and also acts as an agonist at 5-HT1A receptors, a partial agonist at 5-HT1B receptors and an antagonist at 5-HT3, 5-HT1D and 5-HT7 receptors.

Since medications affect everyone differently, it is important to have a variety of treatment options for depression.

Related articles

• FDA approves new drug to treat major depressive disorder (medicalnewstoday.com)
• FDA approves Brintellix to treat depression (theglobaldispatch.com)
• US FDA approves Brintellix to treat MDD: BioSpectrum Asia 1 Oct 2013 (greysteppenwolf.blogspot.com)
• New Antidepressant Approved by the FDA: Brintellix (scienceworldreport.com)
• FDA approves Lundbeck’s antidepressant Brintellix (oddonion.com)